Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C14H22ClN3O3S |
| Molecular Weight | 347.861 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN1CCCC1CNS(=O)(=O)C2=C(OC)C=C(N)C(Cl)=C2
InChI
InChIKey=YSWVLPFCGJOQQA-UHFFFAOYSA-N
InChI=1S/C14H22ClN3O3S/c1-3-18-6-4-5-10(18)9-17-22(19,20)14-7-11(15)12(16)8-13(14)21-2/h7-8,10,17H,3-6,9,16H2,1-2H3
| Molecular Formula | C14H22ClN3O3S |
| Molecular Weight | 347.861 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Lorapride is a centrally acting sulfonamide. It has pharmacodynamic properties that are mainly related to ulcer treatment. On the basis of its psychopharmacologic profile, it has no neuroleptic potential, but it does exhibit some psychostimulating components. After oral administration, absorption of lorapride was rapid. The rate of absorption was first order for solution and zero order for capsule.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4087183
Single dose - 100 mg
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 08:35:27 GMT 2025
by
admin
on
Wed Apr 02 08:35:27 GMT 2025
|
| Record UNII |
549TIC7B4R
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29701
Created by
admin on Wed Apr 02 08:35:27 GMT 2025 , Edited by admin on Wed Apr 02 08:35:27 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
68881
Created by
admin on Wed Apr 02 08:35:27 GMT 2025 , Edited by admin on Wed Apr 02 08:35:27 GMT 2025
|
PRIMARY | |||
|
4909
Created by
admin on Wed Apr 02 08:35:27 GMT 2025 , Edited by admin on Wed Apr 02 08:35:27 GMT 2025
|
PRIMARY | |||
|
68677-06-5
Created by
admin on Wed Apr 02 08:35:27 GMT 2025 , Edited by admin on Wed Apr 02 08:35:27 GMT 2025
|
PRIMARY | |||
|
CHEMBL2105073
Created by
admin on Wed Apr 02 08:35:27 GMT 2025 , Edited by admin on Wed Apr 02 08:35:27 GMT 2025
|
PRIMARY | |||
|
C81599
Created by
admin on Wed Apr 02 08:35:27 GMT 2025 , Edited by admin on Wed Apr 02 08:35:27 GMT 2025
|
PRIMARY | |||
|
C047748
Created by
admin on Wed Apr 02 08:35:27 GMT 2025 , Edited by admin on Wed Apr 02 08:35:27 GMT 2025
|
PRIMARY | |||
|
549TIC7B4R
Created by
admin on Wed Apr 02 08:35:27 GMT 2025 , Edited by admin on Wed Apr 02 08:35:27 GMT 2025
|
PRIMARY | |||
|
DTXSID50867706
Created by
admin on Wed Apr 02 08:35:27 GMT 2025 , Edited by admin on Wed Apr 02 08:35:27 GMT 2025
|
PRIMARY | |||
|
100000082011
Created by
admin on Wed Apr 02 08:35:27 GMT 2025 , Edited by admin on Wed Apr 02 08:35:27 GMT 2025
|
PRIMARY | |||
|
SUB08580MIG
Created by
admin on Wed Apr 02 08:35:27 GMT 2025 , Edited by admin on Wed Apr 02 08:35:27 GMT 2025
|
PRIMARY | |||
|
272-057-1
Created by
admin on Wed Apr 02 08:35:27 GMT 2025 , Edited by admin on Wed Apr 02 08:35:27 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |